Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart Failure
NCT00766857 on ClinicalTrials.gov · last registry update 2015-12-09
A small phase 4 — 27 participants, against a typical 75. The sponsor logged completion for December 2012. Primary outcome, as filed: Cardiac Magnetic Resonance (CMR) will be used to assess global cardiac function (LV ejection fraction). exenatide is approved in the US, but not for heart failure — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P4
- Drug
- exenatideBydureon, Byetta
- Sponsor
- Amsterdam UMC, location VUmc
- Sponsor type
- Other
- Enrollment
- 27
- Started
- 2009-05
- Primary completion
- 2012-12 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Cardiac Magnetic Resonance (CMR) will be used to assess global cardiac function (LV ejection fraction).
Conditions studied
Type 2 Diabetes Mellitus · Congestive Heart Failure
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.